Back to top
more

MacroGenics (MGNX)

(Real Time Quote from BATS)

$15.54 USD

15.54
534,757

-0.53 (-3.30%)

Updated Apr 19, 2024 03:43 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.15%
2Buy18.00%
3Hold9.44%
4Sell5.10%
5Strong Sell2.53%
S&P50011.08%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

4-Sell of 5       4  

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

F Value D Growth A Momentum F VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 38% (96 out of 250)

Industry: Medical - Products

Better trading starts here.

Zacks News

MacroGenics (MGNX) Reports Q4 Loss, Lags Revenue Estimates

MacroGenics (MGNX) delivered earnings and revenue surprises of -188.46% and 58.29%, respectively, for the quarter ended December 2023. Do the numbers hold clues to what lies ahead for the stock?

Analysts Estimate MacroGenics (MGNX) to Report a Decline in Earnings: What to Look Out for

MacroGenics (MGNX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Lantheus Holdings (LNTH) Q4 Earnings and Revenues Beat Estimates

Lantheus Holdings (LNTH) delivered earnings and revenue surprises of 18.24% and 1.02%, respectively, for the quarter ended December 2023. Do the numbers hold clues to what lies ahead for the stock?

MacroGenics (MGNX) Surges 6.8%: Is This an Indication of Further Gains?

MacroGenics (MGNX) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.

MacroGenics' (MGNX) Shares Jump 19% in One Week: Here's Why

MacroGenics (MGNX) shares increase after it reported a surge in Q2 earnings per share. A $50-million milestone payment from Sanofi was also triggered last month.

MacroGenics (MGNX) Reports Q2 Loss, Misses Revenue Estimates

MacroGenics (MGNX) delivered earnings and revenue surprises of 30.77% and 51.46%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?

AdaptHealth Corp. (AHCO) Soars 19.6%: Is Further Upside Left in the Stock?

AdaptHealth Corp. (AHCO) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.

MacroGenics (MGNX) Reports Q1 Loss, Misses Revenue Estimates

MacroGenics (MGNX) delivered earnings and revenue surprises of -157.01% and 81.11%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?

MacroGenics (MGNX) to Report Q1 Results: Wall Street Expects Earnings Growth

MacroGenics (MGNX) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

MacroGenics (MGNX) Surpasses Q4 Earnings Estimates

MacroGenics (MGNX) delivered earnings and revenue surprises of 170% and 3.05%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?

Provention (PRVB) Skyrockets 260% on Buyout Offer From Sanofi

Provention Bio (PRVB) to be acquired by pharma-giant Sanofi (SNY) for $2.9 billion. The transaction is likely to close by second-quarter 2023.

Evolus, Inc. (EOLS) Reports Q4 Loss, Tops Revenue Estimates

Evolus, Inc. (EOLS) delivered earnings and revenue surprises of -14.29% and 0.39%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?

NanoString Technologies (NSTG) Reports Q4 Loss, Tops Revenue Estimates

NanoString (NSTG) delivered earnings and revenue surprises of -55.74% and 3.84%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?

Strength Seen in MacroGenics (MGNX): Can Its 25.7% Jump Turn into More Strength?

MacroGenics (MGNX) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.

SurModics (SRDX) Surges 6.1%: Is This an Indication of Further Gains?

SurModics (SRDX) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.

MacroGenics (MGNX) Stock Sinks As Market Gains: What You Should Know

MacroGenics (MGNX) closed the most recent trading day at $5.70, moving -0.35% from the previous trading session.

Zacks.com featured highlights MacroGenics, NerdWallet and Euronav

MacroGenics, NerdWallet and Euronav have been highlighted in this Screen of The Week article.

Can MacroGenics (MGNX) Climb 74% to Reach the Level Wall Street Analysts Expect?

The average of price targets set by Wall Street analysts indicates a potential upside of 73.9% in MacroGenics (MGNX). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.

Tirthankar Chakraborty headshot

Buy These 3 Top Stocks for Solid Earnings Acceleration

Invest in stocks like MacroGenics (MGNX), NerdWallet (NRDS) & Euronav (EURN) at the moment for superb earnings acceleration.

MacroGenics (MGNX) Recently Broke Out Above the 20-Day Moving Average

Should investors be excited or worried when a stock crosses above the 20-day simple moving average?

Benjamin Rains headshot

Here's How to Find Cheap Stocks Under $10 to Buy for December

Use one of our Zacks screens to find strong, highly-ranked stocks that are trading for under $10 per share to consider buying heading into December and beyond...

Provention (PRVB) Gets FDA Nod for Drug That Delays T1D Onset

Following FDA approval, Provention Bio's (PRVB) Tzield is the first disease-modifying therapy in T1D. Tzield can delay the onset of stage 3 T1D in individuals aged eight years and older.

Zacks.com featured highlights MacroGenics, Olink Holding, NerdWallet, LiveRamp and LivePerson

MacroGenics, Olink Holding, NerdWallet, LiveRamp and LivePerson have been highlighted in this Screen of The Week article.

Wall Street Analysts Believe MacroGenics (MGNX) Could Rally 123%: Here's is How to Trade

The consensus price target hints at a 122.6% upside potential for MacroGenics (MGNX). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.

Tirthankar Chakraborty headshot

5 Best Stocks to Invest in for Solid Earnings Acceleration

Invest in stocks like MacroGenics (MGNX), NerdWallet (NRDS) & LivePerson (LPSN) at the moment for superb earnings acceleration.